OMER OMER

Omeros Stock Price

5.53
0.37 (7.17%)
Upgrade to Real-Time
Regular Market
5.53
Volume 300,399
Bid Price 5.53
Ask Price 5.55
News -
Day High 5.57

Low
5.021

52 Week Range

High
23.85

Day Low 5.14
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.37 7.17% 5.53 12:51:07
Open Price Low Price High Price Close Price Prev Close
5.19 5.14 5.57 5.16
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,529 300,399 $ 5.33 $ 1,602,329 - 5.021 - 23.85
Last Trade Time Type Quantity Stock Price Currency
12:51:07 15 $ 5.53 USD

Period:

Draw Mode:

Omeros Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 345.86M 62.54M 59.96M $ 73.81M $ - -2.40 -2.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 4.20%

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMER Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.186.235.0215.50780,594-0.65-10.52%
1 Month7.517.815.0216.37695,246-1.98-26.36%
3 Months6.408.605.0217.191,088,814-0.87-13.59%
6 Months13.8416.575.0218.421,055,932-8.31-60.04%
1 Year19.8723.855.02112.00844,325-14.34-72.17%
3 Years13.3125.495.02113.69739,409-7.78-58.45%
5 Years9.0427.08825.02115.15794,881-3.51-38.83%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.


Your Recent History
NASDAQ
OMER
Omeros
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.